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The EPIKART study
 A 6-month prospective, randomized, 
double blind, controlled study
 A single injection of KARTILAGE®Cross
or  saline solution
KARTILAGE®Cross
- 2.2 ml (16 mg HA/ml)
- Reticulated
- Biofermentation
- Mannitol (35 mg/g of gel)
Inclusion criteria
 Men or women aged between 45 and 
80 years old
 With symptomatic femoro-tibial OA 
(ACR criteria)
 Lack of efficacy of NSAIDS or 
Paracetamol
 Mean global pain during the last 24 h 
VAS > 40 mm
 K&L II or III
OUTCOMES
 Primary outcome:
The variation of Coll2-1 in serum between inclusion visit 
(D-10) and D90(3 months after injection) expressed as 
the % of patients with a Coll2-1 variation over 10 
nmol/l (∆ D-10 – D90) 
 Secondary outcomes:
- Lequesne Index and pain (VAS) variation
- NSAIDS and paracetamol consumption
- Global patient assessment
- OARSI-OMERACT responders
- Other biomarkers variation: Coll2-1NO2, myeloperoxidase, 
usCRP
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Population
Kartilage®Cross
N=40
Saline solution
N=41
P value
Age (years) 66.9 ± 10.4 63.0 ± 8.9 0.07
Sex
- Women
- Men
62.5 %
37.5 %
75.6 %
24.4 %
0.20
BMI (kg/m2) 29.0 ± 7.4 30.8 ± 7.2 0.24
History (years) 7.6 ± 8 5.9 ± 5.3 0.26
Pain intensity 65.7 ±11.6 66.4 ±10.6 0.77
Characteristics of the FAS population (N=81)
Kartilage®Cross decreased
Coll2-1in the FAS population 
Kartilage®Cross
N=40 at D-10
N=37 at D90
Saline solution
N=41 at D-10
N=35 at D90
P value
Serum Coll2-1 at D-10 
840.3 ± 375.8 
(N=40)
766.1 ± 359.2
(N=41) 
0.3663 
Serum Coll2-1 at D90
745.4 ± 343.5 
(N=37)
782.3 ± 233.7 
(N=35)
0.5975 
Adjustment on basal value -80.2 ± 44.1 -14.6 ± 45.3 0.0030 
Reduction of at least 10 
nmol/l
56.8 % 28.6 % 0.0158 
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Secondary Outcomes
 No significant effect on Pain intensity
 No significant effect on Lesquesne
index
 No significant change in OMERACT-
OARSI responders
 No significant modification of other
biomarkers
Conclusions
 KARTILAGE®Cross induced a significant
reduction of cartilage catabolism 90 
days after treatment.
→ Mechanical effect?
→ Biological activity?
 Coll2-1 is a useful tool for objectively
evaluate viscosupplementation effect
→ sensitive to metabolic change  
occuring in a single joint.
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